248 related articles for article (PubMed ID: 35201613)
1. PET as a Translational Tool in Drug Development for Neuroscience Compounds.
Varrone A; Bundgaard C; Bang-Andersen B
Clin Pharmacol Ther; 2022 Apr; 111(4):774-785. PubMed ID: 35201613
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomographic imaging in drug discovery.
Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
[TBL] [Abstract][Full Text] [Related]
3. The application of positron emission tomography (PET) imaging in CNS drug development.
Suridjan I; Comley RA; Rabiner EA
Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
[TBL] [Abstract][Full Text] [Related]
4. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
[TBL] [Abstract][Full Text] [Related]
5. Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery.
Zimmer L
Expert Opin Drug Discov; 2024 Feb; 19(2):161-172. PubMed ID: 37948046
[TBL] [Abstract][Full Text] [Related]
6. Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy.
Naganawa M; Gallezot JD; Rossano S; Carson RE
Bull Math Biol; 2019 Sep; 81(9):3508-3541. PubMed ID: 29230702
[TBL] [Abstract][Full Text] [Related]
7. Modeling of PET data in CNS drug discovery and development.
Varnäs K; Varrone A; Farde L
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
[TBL] [Abstract][Full Text] [Related]
8. PET technology for drug development in psychiatry.
Arakawa R; Takano A; Halldin C
Neuropsychopharmacol Rep; 2020 Jun; 40(2):114-121. PubMed ID: 32463584
[TBL] [Abstract][Full Text] [Related]
9. Translational PET imaging research.
Hargreaves RJ; Rabiner EA
Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography in CNS drug discovery and drug monitoring.
Piel M; Vernaleken I; Rösch F
J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
[TBL] [Abstract][Full Text] [Related]
11. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates.
Assmus F; Seelig A; Gobbi L; Borroni E; Glaentzlin P; Fischer H
Eur J Pharm Sci; 2015 Nov; 79():27-35. PubMed ID: 26341407
[TBL] [Abstract][Full Text] [Related]
12. Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development.
Xu Y; Li Z
Med Res Rev; 2019 Sep; 39(5):1892-1922. PubMed ID: 30740744
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography molecular imaging for drug development.
Matthews PM; Rabiner EA; Passchier J; Gunn RN
Br J Clin Pharmacol; 2012 Feb; 73(2):175-86. PubMed ID: 21838787
[TBL] [Abstract][Full Text] [Related]
14. Radiochemistry: A Useful Tool in the Ophthalmic Drug Discovery.
Pulagam KR; Gómez-Vallejo V; Llop J; Rejc L
Curr Med Chem; 2020; 27(4):501-522. PubMed ID: 31142249
[TBL] [Abstract][Full Text] [Related]
15. A philosophy for CNS radiotracer design.
Van de Bittner GC; Ricq EL; Hooker JM
Acc Chem Res; 2014 Oct; 47(10):3127-34. PubMed ID: 25272291
[TBL] [Abstract][Full Text] [Related]
16. The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging.
Zhang L; Chen L; Beck EM; Chappie TA; Coelho RV; Doran SD; Fan KH; Helal CJ; Humphrey JM; Hughes Z; Kuszpit K; Lachapelle EA; Lazzaro JT; Lee C; Mather RJ; Patel NC; Skaddan MB; Sciabola S; Verhoest PR; Young JM; Zasadny K; Villalobos A
J Med Chem; 2017 Oct; 60(20):8538-8551. PubMed ID: 28957634
[TBL] [Abstract][Full Text] [Related]
17. Small Molecule PET Tracers in Drug Discovery.
Donnelly DJ
Semin Nucl Med; 2017 Sep; 47(5):454-460. PubMed ID: 28826520
[TBL] [Abstract][Full Text] [Related]
18. Radioligand development for molecular imaging of the central nervous system with positron emission tomography.
Honer M; Gobbi L; Martarello L; Comley RA
Drug Discov Today; 2014 Dec; 19(12):1936-44. PubMed ID: 25173703
[TBL] [Abstract][Full Text] [Related]
19. Likelihood estimation of drug occupancy for brain PET studies.
Schain M; Zanderigo F; Todd Ogden R
Neuroimage; 2018 Sep; 178():255-265. PubMed ID: 29753104
[TBL] [Abstract][Full Text] [Related]
20. Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.
Varnäs K; Juréus A; Johnström P; Ahlgren C; Schött P; Schou M; Gruber S; Jerning E; Malmborg J; Halldin C; Afzelius L; Farde L
J Pharmacol Exp Ther; 2016 Sep; 358(3):464-71. PubMed ID: 27402278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
